Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response

Recurrent mutations at R140 and R172 in isocitrate dehydrogenase 2 (IDH2) occur in many cancers, including ∼12% of acute myeloid leukemia (AML). In preclinical models these mutations cause accumulation of the oncogenic metabolite R-2-hydroxyglutarate (2-HG) and induce hematopoietic differentiation b...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood
Hauptverfasser: Amatangelo, Michael D., Quek, Lynn, Shih, Alan, Stein, Eytan M., Roshal, Mikhail, David, Muriel D., Marteyn, Benoit, Farnoud, Noushin Rahnamay, de Botton, Stephane, Bernard, Olivier A., Wu, Bin, Yen, Katharine E., Tallman, Martin S., Papaemmanuil, Elli, Penard-Lacronique, Virginie, Thakurta, Anjan, Vyas, Paresh, Levine, Ross L.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2017
Schlagworte:
Clinical Trials and Observations
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5553578/
https://ncbi.nlm.nih.gov/pubmed/28588019
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-04-779447
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge